KBC Securities - ONWARD MEDICAL NV (ONWD) Onward Medical FIRST LOOK: ARC-EX becomes available on VA procurement platforms

Report

KBC Securities

Thomas Vranken

Onward Medical FIRST LOOK: ARC-EX becomes available on VA procurement platforms

Onward's ARC-EX system is now available on two federal procurement platforms, including the US Veterans Affairs (VA) and General Services Administration (GSA) Advantage, allowing US government clinics to purchase the system. The inclusion was facilitated by Onward's existing partnership with Lovell. The company remains on track in its commercial launch for the ARC-EX device, hence we reiterate our € 10.4 TP and Buy rating.

29/01/2025 1 EN

Underlying

ONWARD MEDICAL NV

See profile

NL0015000HT4 Euronext Brussels Netherlands

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Thomas Vranken

Other Reports on these Companies

KBC Securities

Morning Notes : COLR BB, FLOB BB, KIN BB, MAAT FP, ONWD BB

: COLR BB, FLOB BB, KIN BB, MAAT FP, ONWD BB

April 1, 2025 April 1, 2025 1 EN

KBC Securities

Onward Medical 2024 was a transformational year, 2025 to scale commercialization

Onward reported its FY24 business update, which underlined a lot of progress yet no major new surprises, and it reaffirms its outlook of main catalysts. Mgmt. confirmed demand is strong, but no commercial outlook was given yet. We look forward to an FDA label expansion for home use in 2025, while we also expect the pivotal Empower BP trial in blood pressure control to kick off. FY24 topline (€ 1.7m) and net result (€ -35.7m) came in line with our expectations, and with a € 60m cash position we believe the company is capitalized with runway into 2H26 (KBCSe). Altogether solid progress in 2024, ...

April 1, 2025 April 1, 2025 1 EN

GlobeNewsWire

ONWARD Medical Reports Full Year 2024 Financial and Operating Results and Shares 2025 Year-to-Date Highlights

ONWARD Medical Reports Full Year 2024 Financial and Operating Results and Shares 2025 Year-to-Date Highlights Received FDA authorization and recorded first commercial sales of ARC-EX System Secured strategic investment from Ottobock and extended cash runway for two years Gained exclusive rights to premier brain-computer interface technology EINDHOVEN, The Netherlands, April 01, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with ...

April 1, 2025 April 1, 2025 1 EN

Ekopak Restatement FY24, balance sheet to be strengthened

After trading was suspended for two days, Ekopak issued a statement announcing the restatement of the FY24 figures published early March. The restatement is linked to reversed revenue recognition linked to Waterkracht. During the FY24 analyst call, management stated no material one-off equipment/engineering sales linked to either Waterkracht or Circeaulair were in the numbers. Hence the material €8m downwards revenue revision comes as a complete surprise. The company further acknowledges that a liquidity shortfall might occur and that the balance sheet will be strengthened opening the door for...

15h / 35m 15h / 35m 1 EN

Guy Sips ... (+7)

Guy Sips
Jacob Mekhael
Lynn Hautekeete
Michiel Declercq
Sharad Kumar S.P
Thomas Couvreur
Wim Hoste

Morning Notes : ACKB BB, AGFB BB, COLR BB, IBAB BB, IVA FP, ONTEX BB, WHATS BB, SHUR BB, EKOP BB, ARG FP

: ACKB BB, AGFB BB, COLR BB, IBAB BB, IVA FP, ONTEX BB, WHATS BB, SHUR BB, EKOP BB, ARG FP

16h / 6m 16h / 6m 1 EN

Jacob Mekhael

Jacob Mekhael

Inventiva FIRST LOOK: Completes NATiV3 enrolment, topline results pinned to 2H26

Inventiva announced the completion of patient enrolment in its phase 3 (NATiV3) trial of lanifibranor (pan-PPAR agonist) in MASH. This is a key milestone, particularly in the context of the difficulties associated with MASH trial recruitment. As a result, the timeline for the topline readout is now pinned to 2H26 taking into account the 72 weeks treatment period. Subject to the second tranche of ~€ 116m from the financing announced in October 2024, which is expected to be triggered in 2Q25, Inventiva will be funded until 3Q26, sufficient to complete its phase 3 trial in MASH. With competitive ...

16h / 21m 16h / 21m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Onward Medical FIRST LOOK: ARC-EX becomes available on VA procurement platforms

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : COLR BB, FLOB BB, KIN BB, MAAT FP, ONWD BB

Onward Medical 2024 was a transformational year, 2025 to scale commercialization

ONWARD Medical Reports Full Year 2024 Financial and Operating Results and Shares 2025 Year-to-Date Highlights

Ekopak Restatement FY24, balance sheet to be strengthened

Morning Notes : ACKB BB, AGFB BB, COLR BB, IBAB BB, IVA FP, ONTEX BB, WHATS BB, SHUR BB, EKOP BB, ARG FP

Inventiva FIRST LOOK: Completes NATiV3 enrolment, topline results pinned to 2H26

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe